1278 related articles for article (PubMed ID: 26141720)
1. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
2. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D as an effective treatment in human uterine leiomyomas independent of mediator complex subunit 12 mutation.
Corachán A; Trejo MG; Carbajo-García MC; Monleón J; Escrig J; Faus A; Pellicer A; Cervelló I; Ferrero H
Fertil Steril; 2021 Feb; 115(2):512-521. PubMed ID: 33036796
[TBL] [Abstract][Full Text] [Related]
4. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
5. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
6. The management of uterine leiomyomas.
Lefebvre G; Vilos G; Allaire C; Jeffrey J; Arneja J; Birch C; Fortier M; Wagner MS;
J Obstet Gynaecol Can; 2003 May; 25(5):396-418; quiz 419-22. PubMed ID: 12738981
[TBL] [Abstract][Full Text] [Related]
7. Epigenomic and enhancer dysregulation in uterine leiomyomas.
Mlodawska OW; Saini P; Parker JB; Wei JJ; Bulun SE; Simon MA; Chakravarti D
Hum Reprod Update; 2022 Jun; 28(4):518-547. PubMed ID: 35199155
[TBL] [Abstract][Full Text] [Related]
8. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
9. Ovarian steroids, stem cells and uterine leiomyoma: therapeutic implications.
Moravek MB; Yin P; Ono M; Coon JS; Dyson MT; Navarro A; Marsh EE; Chakravarti D; Kim JJ; Wei JJ; Bulun SE
Hum Reprod Update; 2015; 21(1):1-12. PubMed ID: 25205766
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic and genetic landscape of uterine leiomyomas: a current view over a common gynecological disease.
Laganà AS; Vergara D; Favilli A; La Rosa VL; Tinelli A; Gerli S; Noventa M; Vitagliano A; Triolo O; Rapisarda AMC; Vitale SG
Arch Gynecol Obstet; 2017 Nov; 296(5):855-867. PubMed ID: 28875276
[TBL] [Abstract][Full Text] [Related]
11. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.
Ono M; Yin P; Navarro A; Moravek MB; Coon JS; Druschitz SA; Serna VA; Qiang W; Brooks DC; Malpani SS; Ma J; Ercan CM; Mittal N; Monsivais D; Dyson MT; Yemelyanov A; Maruyama T; Chakravarti D; Kim JJ; Kurita T; Gottardi CJ; Bulun SE
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17053-8. PubMed ID: 24082114
[TBL] [Abstract][Full Text] [Related]
12. The Epidemiology and Genetics of Uterine Leiomyoma.
Styer AK; Rueda BR
Best Pract Res Clin Obstet Gynaecol; 2016 Jul; 34():3-12. PubMed ID: 26725703
[TBL] [Abstract][Full Text] [Related]
13. Loss of the repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway.
Varghese BV; Koohestani F; McWilliams M; Colvin A; Gunewardena S; Kinsey WH; Nowak RA; Nothnick WB; Chennathukuzhi VM
Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2187-92. PubMed ID: 23284171
[TBL] [Abstract][Full Text] [Related]
14. PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes
Makker A; Goel MM; Mahdi AA; Bhatia V; Das V; Agarwal A; Pandey A
Indian J Med Res; 2016 May; 143(Supplement):S112-S119. PubMed ID: 27748285
[TBL] [Abstract][Full Text] [Related]
15. Introduction of Somatic Mutation in MED12 Induces Wnt4/β-Catenin and Disrupts Autophagy in Human Uterine Myometrial Cell.
El Andaloussi A; Al-Hendy A; Ismail N; Boyer TG; Halder SK
Reprod Sci; 2020 Mar; 27(3):823-832. PubMed ID: 32046450
[TBL] [Abstract][Full Text] [Related]
16. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
17. Growth factors and cytokines in uterine leiomyomas.
Andersen J
Semin Reprod Endocrinol; 1996 Aug; 14(3):269-82. PubMed ID: 8885057
[TBL] [Abstract][Full Text] [Related]
18. MED12 mutations in uterine fibroids--their relationship to cytogenetic subgroups.
Markowski DN; Bartnitzke S; Löning T; Drieschner N; Helmke BM; Bullerdiek J
Int J Cancer; 2012 Oct; 131(7):1528-36. PubMed ID: 22223266
[TBL] [Abstract][Full Text] [Related]
19. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
20. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
